Paul Tudor Jones's CTKB Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 320,715 shares of Cytek Biosciences, Inc. (CTKB) worth $1.4 M, representing 0.00% of the portfolio. First purchased in 2023-Q1, this short-term holding has been held for 5 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in CTKB for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 320,715 shares. Largest reduction occurred in Q4 2025, reducing 249,812 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Cytek Biosciences (CTKB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cytek Biosciences (CTKB) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +320,715 | New Buy | 320,715 | $4.37 |
| Q4 2025 | -249,812 | Sold Out | 0 | $0.00 |
| Q3 2025 | +249,812 | New Buy | 249,812 | $3.47 |
| Q2 2023 | -123,997 | Sold Out | 0 | $0.00 |
| Q1 2023 | +123,997 | New Buy | 123,997 | $0.01 |
Paul Tudor Jones's Cytek Biosciences Investment FAQs
Paul Tudor Jones first purchased Cytek Biosciences, Inc. (CTKB) in Q1 2023, acquiring 123,997 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Cytek Biosciences, Inc. (CTKB) for 5 quarters since Q1 2023.
Paul Tudor Jones's largest addition to Cytek Biosciences, Inc. (CTKB) was in Q1 2026, adding 320,715 shares worth $1.4 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 320,715 shares of Cytek Biosciences, Inc. (CTKB), valued at approximately $1.4 M.
As of the Q1 2026 filing, Cytek Biosciences, Inc. (CTKB) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Cytek Biosciences, Inc. (CTKB) was 320,715 shares, as reported at the end of Q1 2026.